IRIDEX (IRIX) Registration Filing summary

Company overview and business model

• Focuses on ophthalmic medical technology, developing and commercializing products for treating glaucoma and retinal diseases.

• Proprietary MicroPulse and Endpoint Management technologies enable safer, tissue-sparing laser therapy for eye conditions.

• Product portfolio includes laser consoles, delivery devices, and consumable probes for glaucoma, medical retina, and surgical retina applications.

• Generates recurring revenue from single-use laser probes, instrumentation, and service contracts.

• Products are used in hospitals, ambulatory surgical centers, and clinics worldwide.

Financial performance and metrics

• As of July 12, 2024, public float was approximately $34.2 million, based on 15,509,412 shares held by non-affiliates at $2.15 per share.

• 16,636,380 shares of common stock outstanding as of September 3, 2024.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by the selling stockholder; all proceeds go to the selling stockholder.

• Agreed to pay all costs, expenses, and fees related to registering the shares; selling stockholder pays brokerage commissions and similar charges.